Literature DB >> 10981781

Direct costs of blindness in Australia.

S E Wright1, J E Keeffe, L S Thies.   

Abstract

This study calculated the direct financial costs of blindness to the Australian government and community. Three case studies, representative of Australians with severely impaired vision, were used to calculate the annual costs associated with blindness. The costs include pensions, subsidies, concessions, equipment and services. Case I was a retired person with age-related macular degeneration, case 2 a working aged person with diabetic retinopathy, and case 3 a school student with congenital vision impairment. Sensitivity analysis was used to show the possible range of costs for each case. For case I, direct cost was $ 14686 with a range from $9749 to $22507. The cost for case 2 was $17701 ranging from $9669 to $26720. Costs associated with care and education of case 3 were $15948 ranging from $5106 to $23798. In addition to the social costs to a person who is blind, there are significant financial costs to the government and the community that will increase substantially with the ageing of the Australian population.

Entities:  

Mesh:

Year:  2000        PMID: 10981781     DOI: 10.1046/j.1442-9071.2000.00296.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  13 in total

Review 1.  What is the cost of blindness?

Authors:  C Meads; C Hyde
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

Review 2.  Economic cost of age-related macular degeneration: a review of recent research.

Authors:  Kathleen M Ke; Usha Chakravarthy; Ciaran O'Neill
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  How much is the cost of visual impairment: caveat emptor.

Authors:  Catherine Meads; Chris Hyde
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Attitudes toward postmortem cornea donation in Germany: a multicenter survey.

Authors:  C E Uhlig; R Koch; J Promesberger; G Hirschfeld; H Schmidt; B Seitz; T Reinhard; D Böhringer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-09-20       Impact factor: 3.117

5.  Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.

Authors:  C Hopley; G Salkeld; P Mitchell
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

6.  Consequences of amblyopia on education, occupation, and long term vision loss.

Authors:  B Chua; P Mitchell
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

7.  Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.

Authors:  Antoine Lafuma; Antoine Brézin; Stefania Lopatriello; Klaus Hieke; Julia Hutchinson; Viviane Mimaud; Gilles Berdeaux
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

8.  Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants.

Authors:  C Hopley; G Salkeld; J J Wang; P Mitchell
Journal:  Br J Ophthalmol       Date:  2004-04       Impact factor: 4.638

9.  Activity of daily living and its associated factors in war survivors with no visual acuity.

Authors:  Reza Amini; Hamid Haghani; Mehdi Masoomi; Shervin Assari
Journal:  J Res Med Sci       Date:  2010-07       Impact factor: 1.852

10.  Prevalence of visual impairment in relation to the number of ophthalmologists in a given area: a nationwide approach.

Authors:  Antoine J Lafuma; Antoine P Brézin; Francis L Fagnani; Mounir Mesbah; Gilles H Berdeaux
Journal:  Health Qual Life Outcomes       Date:  2006-06-06       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.